The discovery could help to explain why vaccines against hepatitis B fail to work in some individuals and may help to identify those people who need extraprotection.
They seek to improve and prolong the level of protection seen in RV144 by using an extravaccine boost and different adjuvants that may increase and prolong antibody responses.